N-[1-(4-hydroxy-3-isopropylbenzyl)-2-methyl-1H-indol-4-yl]malonic acid | 1000603-09-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: N-[1-(4-hydroxy-3-isopropylbenzyl)-2-methyl-1H-indol-4-yl]malonic acid
• 英文别名: 3-[[1-[(4-Hydroxy-3-propan-2-ylphenyl)methyl]-2-methylindol-4-yl]amino]-3-oxopropanoic acid
• CAS: 1000603-09-7
• 化学式: C₂₂H₂₄N₂O₄
• 分子量: 380.444
• InChiKey: RANBHGYNNSPWIV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  28
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  91.6
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  4-溴-2-异丙基苯酚 在 咪唑 、 正丁基锂 、 氯化亚砜 、 palladium 10% on activated carbon 、 四丁基氟化铵 、 氢气 、 sodium hydride 、 三乙胺 、 sodium hydroxide 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 、 mineral oil 、 正戊烷 为溶剂， 反应 41.0h， 生成 N-[1-(4-hydroxy-3-isopropylbenzyl)-2-methyl-1H-indol-4-yl]malonic acid
  参考文献：
  名称：

  Synthesis and pharmacological characterization of 1-benzyl-4-aminoindole-based thyroid hormone receptor β agonists

  摘要：

  A series of 1-benzylindole-based TR beta agonists were prepared and evaluated. Compounds 11b' and 11c' were found to have cholesterol-lowering in a rat model with marginal effects on cardiac function and HPT axis. The present work illustrates the potential use of indoles as inner ring isosteres. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2013.11.001

文献信息

• COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER DISORDERS
  申请人：Viking Therapeutics, Inc.

  公开号：US20220016136A1

  公开（公告）日：2022-01-20

  The present disclosure is directed toward the use of thyroid receptor agonists of pharmaceutically acceptable salts thereof, in combination with a second pharmaceutical agent for preventing, treating, or ameliorating fatty liver diseases such as steatosis, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis.
• COMPOSITIONS FOR THE TREATMENT OF FIBROSIS AND INFLAMMATION
  申请人：Viking Therapeutics, Inc.

  公开号：US20220016137A1

  公开（公告）日：2022-01-20

  The present disclosure is directed to methods of treating fibrotic conditions and inflammation by administration of TRβ agonists. The disclosure provides methods wherein the abnormal deposition of extracellular matrix components, such as collagen, keratin, or elastin, is reduced, either through interaction of TRβ agonists with TGF-β-dependent inflammatory pathways, or by other mechanisms, thereby ameliorating fibrotic symptoms.
• [EN] COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER DISORDERS<br/>[FR] COMPOSITIONS ET PROCÉDÉS DE TRAITEMENT DE TROUBLES HÉPATIQUES
  申请人：VIKING THERAPEUTICS INC

  公开号：WO2020117987A1

  公开（公告）日：2020-06-11

  The present disclosure is directed toward the use of thyroid receptor agonists of pharmaceutically acceptable salts thereof, in combination with a second pharmaceutical agent for preventing, treating, or ameliorating fatty liver diseases such as steatosis, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis.
• [EN] COMPOSITIONS FOR THE TREATMENT OF FIBROSIS AND INFLAMMATION<br/>[FR] COMPOSITIONS POUR LE TRAITEMENT DE LA FIBROSE ET DE L'INFLAMMATION
  申请人：VIKING THERAPEUTICS INC

  公开号：WO2020117962A1

  公开（公告）日：2020-06-11

  The present disclosure is directed to methods of treating fibrotic conditions and inflammation by administration of TRβ agonists. The disclosure provides methods wherein the abnormal deposition of extracellular matrix components, such as collagen, keratin, or elastin, is reduced, either through interaction of TRβ agonists with TGF-β–dependent inflammatory pathways, or by other mechanisms, thereby ameliorating fibrotic symptoms.
• Synthesis and pharmacological characterization of 1-benzyl-4-aminoindole-based thyroid hormone receptor β agonists
  作者：Naoki Takahashi、Koji Maeda、Yukiyasu Asano、Nobuhide Watanabe

  DOI：10.1016/j.bmc.2013.11.001

  日期：2014.1

  A series of 1-benzylindole-based TR beta agonists were prepared and evaluated. Compounds 11b' and 11c' were found to have cholesterol-lowering in a rat model with marginal effects on cardiac function and HPT axis. The present work illustrates the potential use of indoles as inner ring isosteres. (C) 2013 Elsevier Ltd. All rights reserved.